e-learning
resources
Paris 2018
Wednesday, 19.09.2018
New therapies for respiratory infections: experimental and translational studies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Intrapulmonary pharmacokinetics of laninamivir in healthy subjects: Comparison between a nebulizer and a dry powder inhaler
H. Ishizuka (Tokyo, Japan), H. Furuie (Osaka, Japan), K. Toyama (Tokyo, Japan)
Source:
International Congress 2018 – New therapies for respiratory infections: experimental and translational studies
Session:
New therapies for respiratory infections: experimental and translational studies
Session type:
Poster Discussion
Number:
5454
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Ishizuka (Tokyo, Japan), H. Furuie (Osaka, Japan), K. Toyama (Tokyo, Japan). Intrapulmonary pharmacokinetics of laninamivir in healthy subjects: Comparison between a nebulizer and a dry powder inhaler. 5454
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Efficacy and safety of salbutamol delivered
via
a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects
Source: Eur Respir J 2001; 18: Suppl. 33, 50s
Year: 2001
Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009
Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
Salmeterol pharmacokinetics following a 50-mcg dose by dry powder oral inhalation to healthy volunteers
Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma
Year: 2012
Oral manifestations in asthmatic patients using metered dose inhaler and dry powder inhaler
Source: International Congress 2019 – Innovations in primary care assessment and management
Year: 2019
Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs)
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005
Aerodynamic characteristics of dry powder inhaler (DPI) single-dose combination of budesonide with formoterol
in vitro
study validation
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012
Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler
Source: Eur Respir J 2007; 30: Suppl. 51, 350s
Year: 2007
Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children
Source: Eur Respir J 2002; 20: Suppl. 38, 500s
Year: 2002
Assessment of usability of a novel multi-dose dry powder inhaler in healthy volunteers and mild asthmatics
Source: Eur Respir J 2007; 30: Suppl. 51, 70s
Year: 2007
Comparison of the release characteristics of formoterol dihydrate powder for inhalation delivered through two different types of multidose dry powder inhalers (MDPI)
Source: Eur Respir J 2005; 26: Suppl. 49, 126s
Year: 2005
Young children with asthma treated with budesonide inhalation suspension can successfully be transitioned to once-daily budesonide dry powder inhaler
Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Year: 2007
Clinical equivalence of budesonide delivered
via
two dry powder inhalers
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005
Reliability of inhalation therapy through a multidose dry powder inhaler
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007
Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients
Source: International Congress 2016 – Asthma management
Year: 2016
Pharmaceutical performances of formoterol delivered from a novel multidose dry powder inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 134s
Year: 2001
The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009
A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 156s
Year: 2001
Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009
Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept